Zenuzolac for COVID-19: real-time analysis

Download Image

Post

c19early.org

Zenuzolac for COVID-19

1 study with 90 patients

Serious outcome risk

Zenuzolac

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Zenuzolac studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−200%

Mortality (1)−200%

Hospitalization (1)1%

RCTs (1)−200%

Late (1)−200%

00.511.5+

← Zenuzolac
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Zenuzolac (GLS-1027) is an oral, small molecule isoxazole immunomodulator that down-regulates NF-κB/p38-mediated pro-inflammatory cytokine production and Th17 responses.


Apr 11 2025	Kane et al., NCT04590547	Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection
Apr 11 2025	200% higher mortality (p=0.34), 1% worse recovery (p=0.99), and 1% shorter hospitalization (p=0.87). RCT 132 hospitalized COVID-19 patients showing no significant difference in outcomes with zenuzolac (GLS-1027) treatment.